Search
In case you missed it, here’s a recap of Monday’s highlights from the American Society of Clinical Oncology annual meeting.
On Thursday, June 18th at 6:00 p.m. E.T. with an encore at 9:00 p.m., MSK will stream a special performance highlighting poignant and humorous perspectives On Cancer and Coronavirus, featuring works from its writing program, Visible Ink.
An experimental drug for acute myelogenous leukemia might potentially help many more patients than previously thought by controlling epigenetic processes, according to a recent MSK study.
The MD Anderson Cancer Center presented its annual award to Dr. Scheinberg in recognition of his pioneering work in developing chemotherapeutic agents for leukemia and other cancers.
At Memorial Sloan Kettering Cancer Center’s 43rd annual event recognizing graduates and award winners, honorees were welcomed back to an in-person event.
Memorial Sloan Kettering Cancer Center (MSK) today announced that the New York State Department of Health has issued approval for a new molecular assay, Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS). MSK-ACCESS was developed within the Marie-Josee and Henry R. Kravis Center for Molecular Oncology (CMO) and the test has been clinically validated and implemented by members of MSK’s Molecular Diagnostics Service.
Memorial Sloan Kettering Cancer Center (MSK) today announced that Rémy Evard has joined as its new Chief Digital Officer and Head of Technology.
Sloan Kettering Institute investigators have learned how Hedgehog proteins, which are important in both development and cancer, are assembled.
Immunotherapy drugs called checkpoint inhibitors have been a game changer for some people with cancer. But for most patients, these drugs have been disappointing. Researchers are trying to figure out why.